Trials / Active Not Recruiting
Active Not RecruitingNCT05336266
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
IIT2021-16-Hendifar-KetoROCX: A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Andrew Hendifar, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.
Detailed description
The main things that will happen in this study are: patients will be administered ketorolac for 5 days, blood draws, completion of questionnaires, monitoring physical activity and sleep by wearing a study-provided FitBit along with weight using a study-provided smart scale.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketorolac Tromethamine | Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2025-02-19
- Completion
- 2026-12-05
- First posted
- 2022-04-20
- Last updated
- 2026-01-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05336266. Inclusion in this directory is not an endorsement.